Form 4: Seres Therapeutics Director Kurt Graves Acquires 100,000 Stock Options
SEC Form 4 Filing
Director Kurt Graves acquired 100,000 stock options in Seres Therapeutics, Inc. on April 10, 2025.
Summary
- On April 10, 2025, Kurt Graves, a director of Seres Therapeutics, Inc., acquired 100,000 stock options.
- The options have an exercise price of $0.58.
- The options vest fully on the earlier of April 10, 2026, or the day before the company's 2026 annual meeting of shareholders.
- The options expire on April 9, 2035.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a routine disclosure of stock option grants to a director, which is a common practice.
Industry Context
This is a standard Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. It's a routine part of corporate governance and provides transparency to the market.
Stakeholder Impact
- The acquisition of stock options by a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 04/10/2025 | Date of transaction: Kurt Graves acquired 100,000 stock options. |
| 04/10/2026 | Earliest vesting date for the stock options. |
| 04/09/2035 | Expiration date of the stock options. |
| 04/11/2025 | Date of Form 4 filing. |
Keywords
stock options, Form 4, director, MCRB, Seres Therapeutics, acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.